American College of Clinical Pharmacy
      Search      Cart


NIH Panel Releases New Statement on Bebtelovimab for the Treatment of High-Risk Patients With Mild to Moderate COVID-19

March 02, 2022

The COVID-19 Treatment Guidelines Panel (the Panel) has updated its recommendations to provide clinicians with guidance on the role of bebtelovimab as an additional treatment option for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease.

The Panel favors ritonavir-boosted nirmatrelvir, sotrovimab, or remdesivir as the preferred therapies for these patients. However, if none of these therapies are available, feasible to deliver, or clinically appropriate, the Panel recommends using either bebtelovimab or molnupiravir as an alternative therapy.

For complete details, see the full statement on the COVID-19 Treatment Guidelines website.


This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.